CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
We are very excited to launch our new website! Please take a few moments to click around and explore...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...